Recently, the 2026 Shenzhen International High-Performance Medical Device Exhibition and Innovative Drug Exhibition (Hong Kong Edition) and the 5th Hong Kong International Biotechnology Forum and Exhibition (BIOHK2026) opened jointly at the Hong Kong Convention and Exhibition Centre.

Recently, Kexing Biopharm traveled to the United Kingdom with the Shandong Provincial delegation to take part in the inaugural "Shandong Week in the UK 2026," hosted by the People's Government of Shandong Province and organized by the Foreign Affairs Office of the Provincial Government.

Recently, Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly owned subsidiary of Kexing Biopharm, received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA). The notice approves clinical trials of GB20 Injection, an innovative anti-TL1A monoclonal antibody independently developed by Shenzhen Kexing, for the indication of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).

On September 11, a Latin American healthcare delegation organized by the Guangdong–Hong Kong–Macao Greater Bay Area International Clinical Trial Center visited Kexing Biopharm for a site tour and exchange under the theme "Boundless Innovation · Smarter Health."

Recently, Kexing Biopharm’s international product Paclitaxel for Injection (Albumin-Bound) (Apexelsin®) successfully passed the review by the Drug Safety Center of the Ministry of Health of the Republic of Uzbekistan and received its drug registration certificate, marking another important milestone in the company’s internationalization.

Recently, Kexing Biopharm and Visum Pharmaceutical Co., Ltd. (“visumpharma”) officially signed a commercialization cooperation agreement for Metoprolol Succinate Extended-Release Tablets in the Hong Kong market of China.

Following a public announcement from August 14 to August 20, 2026, the Jinan Pilot-Scale Platform for Protein Drugs, established by Kexing Biopharm, was included in the official list of recognized platforms.

On July 24, The 1st China Pharmaceutical innovation Conference 2026 was successfully held.